{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:52:22Z","timestamp":1780581142774,"version":"3.54.1"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"Abstract<\/jats:title>Severe thrombocytopenia (platelets <50\u00a0\u00d7\u00a0109<\/jats:sup>\/L) is associated with very poor outcome of patients with myelofibrosis (MF<\/jats:styled-content>). As patients with primary myelofibrosis (PMF<\/jats:styled-content>) differ from patients with postessential thrombocythemia (PET<\/jats:styled-content>\u2010MF<\/jats:styled-content>) and postpolycythemia vera myelofibrosis (PPV<\/jats:styled-content>\u2010MF<\/jats:styled-content>), we aimed to evaluate the significance of low platelets among these patients. We present clinical characteristics and outcome of patients with either PMF<\/jats:styled-content>, PPV<\/jats:styled-content>\u2010MF<\/jats:styled-content>, or PET<\/jats:styled-content>\u2010MF<\/jats:styled-content>, and thrombocytopenia who presented to our institution between 1984 and 2015. Of 1269 patients (877 PMF<\/jats:styled-content>, 212 PPV<\/jats:styled-content>\u2010MF<\/jats:styled-content>, 180 PET<\/jats:styled-content>\u2010MF<\/jats:styled-content>), 11% and 14% had platelets either <50\u00a0\u00d7\u00a0109<\/jats:sup>\/L or between 50\u2010100\u00a0\u00d7\u00a0109<\/jats:sup>\/L, respectively. Patients with platelets <50\u00a0\u00d7\u00a0109<\/jats:sup>\/L were most anemic and transfusion dependent, had highest blast count and unfavorable karyotype. In general, their overall and leukemia\u2010free survival was the shortest with median time of 15 and 13\u00a0months, respectively; with incidence of acute leukemia almost twice as high as in the remaining patients (6.9 vs 3.6 cases per 100 person\u2010years). Nevertheless, this observation remains mostly significant for patients with PMF<\/jats:styled-content>, as those with PEV<\/jats:styled-content>\/PVT<\/jats:styled-content>\u2010MF<\/jats:styled-content> have already significantly inferior prognosis with platelets <100\u00a0\u00d7\u00a0109<\/jats:sup>\/L.<\/jats:p>","DOI":"10.1111\/ejh.13005","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T07:46:49Z","timestamp":1512978409000},"page":"257-263","source":"Crossref","is-referenced-by-count":56,"title":["Significance of thrombocytopenia in patients with primary and postessential thrombocythemia\/polycythemia vera myelofibrosis"],"prefix":"10.1111","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-4196","authenticated-orcid":false,"given":"Lucia","family":"Masarova","sequence":"first","affiliation":[{"name":"Department of Leukemia University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4669-0233","authenticated-orcid":false,"given":"Ahmad","family":"Alhuraiji","sequence":"additional","affiliation":[{"name":"Kuwait Cancer Control Center Shuwaikh Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09179.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(90)90007-F"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-158386"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.9316"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02796.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0609.2004.00386.x","article-title":"Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis","volume":"74","author":"Benetatos L","year":"2005","journal-title":"Eur J Haematol"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310523"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.005"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01373.x"},{"issue":"15","key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1200\/JCO.2016.34.15_suppl.7068","article-title":"Clinical features and outcome of patients with poor\u2010prognosis myelofibrosis based on platelet count <50\u00a0\u00d7\u00a0109\/L: a single\u2010center experience in 1100 myelofibrosis patients","volume":"34","author":"Alhuraiji A","year":"2016","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14601"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404914"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.87"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.093765"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.169"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.101733"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8833"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.374"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.06.001"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-81"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1046867"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T11:32:28Z","timestamp":1695727948000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,17]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/ejh.13005"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13005","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,17]]}}}